Objective:
To enhance drug delivery processes by integrating patient needs earlier in drug development and fostering collaboration among industry, academia, and healthcare authorities.
Approach:
- Symposia: Organizing complimentary one-day symposia on specific drug delivery topics to facilitate discussions among industry and academia.
- Working Groups: Forming consortia to address key drug delivery issues and improve collaboration among companies and academic institutions.
- Patient Advocacy: Initiating projects, such as collaboration with the Lung Cancer Alliance, to gather patient feedback on treatment regimens.
Key Findings:
- Symposia have attracted over 100 attendees, providing valuable networking and learning opportunities.
- 95% of participants believe drug delivery technology solutions should be determined during pre-clinical and Phase I development.
- The Non-invasive Macromolecule Delivery Consortium (NMDC) has made progress in improving adherence for large-molecule injectable drugs.
Interpretation:
The Institute aims to connect drug development with patient experience by prioritizing patient needs and fostering collaboration among industry, academia, and healthcare authorities.
Limitations:
- The article does not provide quantitative data on the impact of the initiatives.
- Future plans are outlined but lack specific timelines or measurable outcomes.
Conclusion:
The Institute is focused on enhancing drug delivery through education, collaboration, and patient involvement in the development process.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.